OxySure Therapeutics

December 4, 2015

Market Data

Fiscal Year December
Industry Medtech
Market Cap $9.1M
Price/Earnings (ttm) N/A
Price/Book (mrq) 3.8x
Price/Sales (ttm) 2.7x
Insider Ownership 46.1%
Shares Outstanding 36.2M
Equity Float 13.5M
Avg. Volume (3 mo.) 178,562
As of December 4, 2015

Income Statement Snapshot

Revenue (TTM) $3.4M
Gross Profit $1.4M
Gross Margin 42.5%
Net Income (TTM) ($5.7M)

Balance Sheet Snapshot

Cash $2.0M
Debt $1.2M

OxySure Therapeutics Inc. is a medical technology company focused on the design, manufacture and distribution of specialty respiratory and medical solutions. The Company has developed a unique platform technology, whereby medically pure oxygen is created instantly from two dry, inert powders, allowing oxygen to be delivered on demand. The launch product using this technology is called the OxySure Model 615.With Model 615, there are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, and no required training, and the technology is both safe and easy-to-use for the layperson. Similar to an automated external defibrillator (AED) or fire extinguisher, it can be placed just about anywhere a medical emergency might occur to help improve medical outcomes and save lives by bridging the gap between a medical emergency and the arrival of first responders on the scene.

Our price target is $1.35, representing upside of over 600%. OXYS has developed a groundbreaking, first-to-market technology that has the potential to achieve a multimillion unit install base. The OxySure Model 615 is far cheaper than an AED ($349 price for a Model 615 vs. $1,500 for an AED), which makes it more accessible and affordable than AEDs, potentially leading to larger market acceptance as more end users become aware of the technology. Twelve consecutive quarters of revenue growth indicates strong market interest, which we anticipate will accelerate as OXYS increases its sales and marketing spend. Multiple analysts have target prices that indicate strong share price upside for OXYS, including Zacks Small-Cap Research (TP: $1.75), Taglich Brothers (TP: $2.10), SeeThru Equity (TP: $2.30), and Sterling Investment Services (TP: $1.90).

  • OxySure's Model 615 is a pioneering technology that is defining a new market with no direct competition
    • A robust patent portfolio should ensure the Company maintains this advantage over the long-term

  • Targeted for use in enormous end markets
    • End markets are at least as large as the install base for AEDs, which exceeds two million units, and potentially as large as the fire extinguisher based, which exceeds 100 million units in the U.S. (500+ million units globally)

  • 3Q15 revenue was up 39% YoY and 9% QoQ to $1.1 million
    • Fourteen consecutive quarters of revenue growth (five quarters of triple digit growth and seven quarters of double digit growth during this time period)

  • Projecting a $10 million revenue run rate by year-end 2016
    • Aggressively expanding sales team to 25 territory managers; each manager expected to add $500,000 in sales per annum
    • OXYS expects to reach cash flow and GAAP breakeven in 2016

  • OxySure's Model 615 has been cleared by the U.S. Food & Drug Administration for over-the-counter sales, along with receiving CE Marking approval

  • Recurring revenue model leads to greater earnings predictability
    • OxySure's Model 615 consists of a reusable housing and a replaceable cartridge, which must be replaced after each use or upon expiry of a 2-year shelf life

Company Client Page

Investor Contact Info:
RedChip Companies, Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256



"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market